Wang Jie
Angel Investor
China
Wang Jie is a Series A investor in China focused on Health Care and Biotechnology. Co-founder of SyMap Medical.Dr. Wang is an established and a well known expert in cardiovascular research and the industry. He was the pioneer to introduce biotechnology and biopharmaceuticals into China, funded and led three companies in China to manufacture recombinant protein drugs and interventional cardiology devices, respectively. Dr. Wang has served as a consultant to a number of the world’s largest pharmaceutical companies, venture capital firms, start-up companies and consulting firms. He guided key animal experiments and first-in-human studies in China to prove the concept of Ardian’s renal denervation therapy for hypertension, heart failure and other cardiovascular diseases. He has been awarded “CRT 2012 Best Innovation Award” due to his patents of renal sympathetic nerve mapping/ablation devices. His leadership in both academia and industry has been demonstrated by his extraordinary carrier path: an associate professor at Columbia University, the Dean of Medical School of Nanjing University, Associate Director of the Skirball Center for Cardiovascular Research, Executive Vice President of Institute of Clinical and Translational Research/Jiangsu Province Hospital, and a co-founder of SyMap Medical Ltd (Approved for “Fast Track” by CFDA; invested by Sequoia and Softbank).
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Wang Jie invests in
Stages Wang Jie invests in
Countries Wang Jie invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (100%)
- Biotechnology 1 (100%)
- Medical Device 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| SyMap is dedicated to developing a proprietary, catheter-based renal mapping and ablation system for renal denervation therapy to treat hypertension and other diseases, such as heart failure, arrhythmia, and renal failure. | Series A / Mar 18, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Wang Jie invest in?
Wang Jie invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Wang Jie?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Wang Jie last invest?
The most recent investment recorded for Wang Jie closed in Mar 2014. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
